Business Wire

Philips Launches Latest Version of Its Speech-to-Text Service

4.7.2017 10:02 | Business Wire

Jaa

Speech Processing Solutions, the world number one for professional dictation solutions, has launched a brand new version of their Philips SpeechLive dictation workflow software. The latest release offers a fully-integrated speech recognition and transcription service which turns recordings into text even faster. Voice recordings can be made anywhere using voice recorders or a mobile app and turned into written documents quickly, saving time and resources for busy users.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170704005011/en/

Philips SpeechLive (Photo: Business Wire)

Philips SpeechLive (Photo: Business Wire)

Philips SpeechLive increases flexibility and productivity

The new update brings multiple advantages to both the account administrators as well as the individual users. “Based on our customers’ highly valuable feedback, we have implemented new changes to our system which will make creating documents even easier and quicker than before” explained Dr. Thomas Brauner, CEO of Speech Processing Solutions. Authors and transcriptionists now benefit from an extensive array of new options, including adjustable pop-up notifications, search and filter functions, an archive folder and a full online player for every user.

Transcriptionists benefit from new enhancements

Transcriptionists now have even more control over their work settings and can adjust them according to their needs. They will also benefit from auto backspace and adjustable winding speed settings, direct access to all of the authors’ dictations within a new folder tree-view and foot control configurability. “Should you need something transcribed when your assistant is out of the office, ill or simply too busy, our highly trained transcriptionist staff will take care of it for you” continues Dr Brauner. Recordings can be sent to the Philips SpeechLive Transcription Service at any time with short turnaround times.

Improved usability for account administrators

Account administrators will be able to add and amend users even easier and quicker than before. Some of the advantages of the latest update include a reduced number of required clicks to add subsequent users, as well as a better overview of user activation status and configurable automatic archiving of transcribed dictations.

Recorder app offers full mobility

Philips also brought out a new update of their voice recorder app, which can be used to record notes and ideas from anywhere. The free dictation app offers premium recording quality and new professional features such as inserting or cutting out specific sequences, easy share functions as well as a special car mode, for safe and convenient use whilst driving. “Whether we just walk out of court, we are in another office or at home, it doesn´t matter. We are able to send our dictations immediately to our secretaries for transcription,” says Dan Hutchinson, Managing Director at Cooke and Hutchinson, a renowned Australian law firm.

For a free trial of Philips SpeechLive visit:

www.speechlive.com

www.philips.com/dictation

About Speech Processing Solutions

Speech Processing Solutions is the global number one in professional dictation solutions. Founded in Austria in 1954 as part of Philips, the company has been the driving force behind innovative speech-to-text solutions for over 60 years. The company has developed ground-breaking products, such as the mobile Philips SpeechAir device, the Philips PocketMemo voice recorder, the Philips SpeechMike Premium USB dictation microphone and the Philips voice recorder app for smartphones, thus delivering its promise of excellence and outstanding quality. Thanks to the latest innovation, Philips SpeechLive, designed as a cloud-based workflow solution, recording dictations is quicker and easier than ever. The tailored range of products and services offered by Speech Processing Solutions helps professional users to save time and resources and to work at maximum efficiency.

Follow Speech Processing Solutions:

Facebook: http://www.facebook.com/philipsvoicetracer

Instagram: https://www.instagram.com/philips_dictation/

Twitter @speech_com: http://www.twitter.com/speech_com

YouTube: http://www.youtube.com/philipsdictation

LinkedIn: http://www.linkedin.com/company/speech-processing-solutions

Contact information

Speech Processing Solutions
Lea Pachta
lea.pachta@speech.com
Tel: +43 160529-1744
www.philips.com/dictation

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and HUMIRA®27.7.2017 16:00Tiedote

Boehringer Ingelheim announced today that the first patient has been enrolled into its VOLTAIRE-X interchangeability study. The goal of the study is to demonstrate that BI 695501 is interchangeable with the U.S.-marketed formulation of Humira®* 40mg/0.8mL. This is the first study in the U.S. to investigate an interchangeability designation for an adalimumab biosimilar candidate. The study will compare the pharmacokinetics and clinical outcomes between patients receiving Humira® continuously, versus those who switch repeatedly between Humira® and BI 695501, Boehringer Ingelheim’s adalimumab biosimilar candidate.1 The study will also assess safety, immunogenicity and efficacy.1 “We are pleased that the first patient has now been enrolled in VOLTAIRE-X, and look forward to continued recruitment and patient follow-up,” said Ivan Blanarik, Senior Vice President and Head of

Acxiom Launches Connected Spaces27.7.2017 15:30Tiedote

Today, Acxiom® (Nasdaq: ACXM), in collaboration with Adobe, announced the launch of Connected Spaces, a global solution aimed at delivering more relevant omnichannel experiences to customers. Connected Spaces is designed to revolutionise customer experience and business returns for retail, travel and leisure locations such as airports, malls, sports stadiums, concert arenas and resorts. A pioneering example is Heathrow airport. Heathrow is able to deliver more relevant communications to customers in real-time as part of its overall engagement strategy and is already generating exceptional results including an increase in spend of 20-25 percent for engaged customers. Common to airports, malls and the like is a high footfall of consumers who intend to visit multiple concession, franchise, or subcontracted brands operating in their environments. This can translate to a relative

Watch BizWireTV: Helix Brings DNA Kits to the Public and Michael Kors Gets Ready to Buy Jimmy Choo27.7.2017 15:08Tiedote

On the latest BizWireTV, catch the latest Quick Biz Hits. Also see what’s happening in the startup world with the Accelerator Report, featuring the VC Watch and this week’s Startup Standout. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170727005456/en/ BizWireTV is hosted by Jordyn Rolling (Photo: Business Wire) Now you can watch BizWireTV, and the latest breakthroughs in tech from the biggest brands, on any screen you want by downloading the new app through the Apple TV and iPhone App Store and Google Play for Android devices. Top of the Wire Helix launches first online consumer marketplace for DNA-powered products that offer insights on ancestry, entertainment, family, fitness, health and nutrition. Watch BizWireTV to

European Commission Grants Orphan Drug Designation to Allena Pharmaceuticals’ Investigational Therapy for the Treatment of Primary Hyperoxaluria27.7.2017 14:05Tiedote

Allena Pharmaceuticals, Inc., a specialty biopharmaceutical company dedicated to bringing first in class, specific, non-absorbed, oral enzyme therapeutics to patients with serious renal, urologic and orphan diseases, announced today that the European Commission has granted orphan drug designation to Allena’s investigational product ALLN-177, Bacillus subtilis oxalate decarboxylase, for the treatment of primary hyperoxaluria (PH). The orphan designation was granted to Allena Pharmaceuticals Ireland Limited, a subsidiary of Allena Pharmaceuticals, Inc. Allena’s lead compound ALLN-177, is being developed to treat patients with severe hyperoxaluria, a condition characterized by markedly elevated urinary oxalate excretion. PH, a type of severe hyperoxaluria, is a rare genetic disorder caused by endogenous overproduction of oxalate by the liver that can result in kidney stone disease, kidney

Subscription Period for Superior Industries’ Tender of UNIWHEELS AG’s Shares to Close Monday, July 31, 201727.7.2017 09:00Tiedote

Superior Industries International, Inc. (NYSE:SUP), one of the world’s largest manufacturers of aluminum wheels, reiterated today that the subscription period for the tender offer to acquire all remaining outstanding shares of UNIWHEELS AG (“UNIWHEELS”) will close Monday, July 31, 2017. On June 30, 2017, Superior announced it had commenced a tender offer to acquire the remaining 954,920 shares held by the public shareholders, which represents approximately 7.7% of the total outstanding shares of UNIWHEELS, for cash consideration of 247.87zl per share. Superior acquired the other approximately 92.3% of the outstanding shares through a tender offer that was settled on May 30, 2017, where the public shareholders also received cash consideration of 247.87zl per share. Following the settlement of the tender offer, Superior will finalize the proceedings to delist UNIWHEELS’ common stock from

Ipsen Delivers Strong Sales Growth of 18.8%1 in the First Half of 2017 and Upgrades Its Guidance for Full Year 201727.7.2017 08:00Tiedote

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced financial results for the first half of 2017. H1 2017 Highlights Strong operating performance of 18.8%1 Group sales growth and Core Operating Income margin improvement by 1.2 points to 26.2% of sales Specialty Care sales growth of 23.1%1 reflects continued Somatuline® momentum and includes contribution of key new products Cabometyx® and Onivyde® Consumer Healthcare sales growth of 1.3%1 including contribution of newly acquired products Upgraded full year 2017 guidance of Specialty Care sales growth greater than 24.0%1, slight growth1 of Consumer Healthcare sales, and Core Operating Income margin greater than 25.0% o

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme